Select Page ::

Ken Aldren S. Usman The Conversation – The Conversation

Posted on April 18, 2022 by Prof Baldwin

Profile Articles Activity

I am currently a PhD candidate at the Institute for Frontier Materials, Deakin University under the supervision of Prof. Joselito M. Razal. Prior to joining Deakin, I have received my Bachelor's and Master's degrees from the University of the Philippines (UP) in 2013 and 2018, respectively. Currently, my PhD work focuses on developing MXene-based composite fibers, which is considered among the hottest and most-studied nanomaterials, with application in multiple fields such as energy storage, structural composites, environmental remediation and nanomedicine.

Through both of my Masters and PhD courses, I have authored/co-authored 28 research articles. 19 of these papers where published during my Phd, including 3 first-authored journal articles, 3 first-authored review articles and 1 article as corresponding author. At the end of 2021, I received the Excellence in Research Award during IFM Staff and HDR Awards as a result of my outstanding research outcomes during that year. Now, I am at the tail end of my PhD and is expected to finish and submit a thesis by July 2022. As one of the seniors, I was recently assigned as the Student Representative, for our institutes Education and Training Sub-committee, where I primarily represent IFMs PhD students in committee meetings. This position also allowed me to get involved in creating policies and training program dedicated for developing and overseeing a younger generation of IFM students. I am hoping that after PhD, I could continue my research here and Australia and further contribute to the growing field of smart/functional textiles.

Editor’s choice: recent research highlights from the International Journal of Nanomedicine – Dove Medical Press

Posted on June 22, 2017 by Prof Baldwin

Farooq A Shiekh,1 Abdul-Rahman M Abu-Izzah,2 Vivian J Lee,2 Syed Mudassar1

1Department of Clinical Biochemistry, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, India; 2Department of Basic Medical Sciences, Avalon University School of Medicine, Curacao, the Netherlands Is nanomedicine really less harmful? Evaluation of: Thakkar A, Chenreddy S, Thio A, Khamas W, Wang J, Prabhu S. Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice. Int J Nanomedicine. 2016;11:32653276. Nanomedicine1 has increasingly received a tremendous attention over the past two decades as a potential multidimensional field, developing nano-applications that are transforming a host of medical products and services,2,3 including drug delivery4 and health-monitoring devices, and the possibility of gaining new insights about undruggable targets and treatment through atomic-scale precision is increasing rapidly.5 Although it is uncertain as to which of the new delivery platforms will become the most effective and useful, it is certain that many new approaches will be investigated in the years to come.4,6

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

View original post here:
Editor's choice: recent research highlights from the International Journal of Nanomedicine - Dove Medical Press

Healthcare Nanotechnology (Nanomedicine) Market Size 2021, Statistics, Trends, Regional Analysis by Key Players | Industry Forecast to 2027 The…

Posted on February 14, 2021 by Prof Baldwin

Request Download SampleAsk For DiscountPricing & Purchase Options

Healthcare Nanotechnology (Nanomedicine) Market was valued at USD 156.40 Billion in 2019 and is projected to reach USD 449.10 Billion by 2027, growing at a CAGR of 14.10% from 2020 to 2027.

The Healthcare Nanotechnology (Nanomedicine) Market report published by Verified Market Research offers an industry-wide assessment of the Healthcare Nanotechnology (Nanomedicine) market that contains the key factors contributing to the growth of the Healthcare Nanotechnology (Nanomedicine) industry. The latest Healthcare Nanotechnology (Nanomedicine) market research report provides an in-depth analysis of the micro and macroeconomic indicators influencing the development of the world market in the forecast period 2021-2027

The current trends in the Healthcare Nanotechnology (Nanomedicine) market combined with a variety of growth opportunities, key drivers, restraints, challenges, and other critical aspects have been clearly set out in the Healthcare Nanotechnology (Nanomedicine) market report. Additionally, the report takes into account various market dynamics, which in turn creates a variety of development prospects for the major players in the Healthcare Nanotechnology (Nanomedicine) industry.

The latest report is the latest study to offer 360 coverage of the Healthcare Nanotechnology (Nanomedicine) industry, which has been hit by the negative economic impact of the COVID-19 outbreak since the beginning of this year.

The Main Companies Featured in this Report are:

Sanofi SA Pfizer Inc. Celgene Corporation Luminex Corporation Taiwan Liposome Company Ltd.

Overview of the Healthcare Nanotechnology (Nanomedicine) report:

The Healthcare Nanotechnology (Nanomedicine) market has been broadly segmented to give readers a deeper understanding of the various facets and characteristics of the market. The size of the market for new entrants and incumbents has been assessed using a variety of analytical tools including SWOT analysis, investment valuation, and Porters Five Forces analysis. In addition, the authors of the report in the study assessed the financial situation of the most important companies operating in this sector. They provided important information on gross profit, share of sales, sales volume, production costs, individual growth rate and many other financial metrics of these competitors.

Healthcare Nanotechnology (Nanomedicine) Market Report Scope

Healthcare Nanotechnology (Nanomedicine) Market Segmentation

Healthcare Nanotechnology (Nanomedicine) Market By Application

Drug Delivery Biomaterials Active Implants Diagnostics Imaging Tissue Regeneration Other

Global Healthcare Nanotechnology (Nanomedicine) Market By Disease

Cardiovascular Diseases Oncological Diseases Neurological Diseases Orthopedic Diseases Infectious Diseases Other

Different industry analysis tools such as SWOT and Porters five techniques have been used for examining the important aspects of the Healthcare Nanotechnology (Nanomedicine) market. Moreover, different development plans and policies, rules and regulations are also incorporated in the research report. For a stronger and effective outlook of the Healthcare Nanotechnology (Nanomedicine) market, this report has been elucidated with effective info-graphics such as graphs, charts, tables and pictures.

The Healthcare Nanotechnology (Nanomedicine) market have been examined across several global regions such as North America, Latin America, Middle East, Asia-Pacific, Africa and Europe. The degree of competition among top key players has been described by presenting all-informative data of global key players. Furthermore, it makes use of graphical presentation techniques for presenting the essential facts during study of Healthcare Nanotechnology (Nanomedicine) market. Collectively, this innovative research report helps to make well informed business decisions in the businesses.

Visualize Healthcare Nanotechnology (Nanomedicine) Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Important Highlights:

*** The report provides actionable information about the production capacity, estimated growth, and revenue of the regional market that has accumulated over the forecast period.

*** The report provides key information related to market dynamics such as product price patterns, total revenue generated and expected growth rate.

*** The report highlights the spectrum of competition in the Healthcare Nanotechnology (Nanomedicine) market and focuses on the company profiles of the major competitors in the market.

*** The report highlights the product portfolios along with the respective specifications and uses of those products by each market participant.

*** In addition, the production capacities, gross margins, manufacturing costs, pricing models and sales shares of these market participants were discussed.

Thank you for reading our report. The report can be adapted according to customer requirements. Please contact us to learn more about the report.

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website:- https://www.verifiedmarketresearch.com/

Follow this link:
Healthcare Nanotechnology (Nanomedicine) Market Size 2021, Statistics, Trends, Regional Analysis by Key Players | Industry Forecast to 2027 The...

Latest updates on the research activities at KING SKYFRONT, Japan. – Yahoo Finance

Posted on October 31, 2021 by Prof Baldwin

KAWASAKI, Japan, Oct. 29, 2021 /PRNewswire/ -- Researchers affiliated with Kawasaki INnovation Gateway at SKYFRONT (KING SKYFRONT) and their collaborators report on antibody delivery technology that empowers immunotherapy against glioblastoma and suppresses side effects, and creating smart nanomachines to detect highly invasive cancer after surgery and prevent recurrence.

Tumor-Specific Anti-Cancer Activity

Details

https://tonomachi-ksf.kawasaki-net.ne.jp/ennewsletter/

Research highlight

Antibody Delivery Technology Empowers Immunotherapy against Glioblastoma and Suppresses Side Effects

In this research, Kazunori Kataoka of the Innovation Center of Nanomedicine, Kawasaki, Japan and colleagues developed an antibody delivery technology based on multiple glucosylated polymers conjugated onto antibodies via linkers cleaving in tumor microenvironment.

The delivery technology enhanced the accumulation of anti-PD-L1 antibody (Avelumab) in glioblastoma by 33-fold, compared to unmodified Avelumab by recognizing Glucose Transporter 1.

In orthotopic glioblastoma models, a single administration of the modified Avelumab at 15% of the standard dose achieved 60% complete response rate, with long-term immune memory.

The delivery technology suppressed the immune-related adverse events of Avelumab.

Reference

Yang, T., Mochida, Y., Liu, X. et al. Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma. Nat Biomed Eng (2021).

DOI: 10.1038/s41551-021-00803-z

URL: https://doi.org/10.1038/s41551-021-00803-zhttps://tonomachi-ksf.kawasaki-net.ne.jp/pdf/pressrelease02.pdf

Research highlight

Creating Smart Nanomachines to Detect Highly Invasive Cancer After Surgery and Prevent RecurrenceCancer Metastasis and Recurrence Prevention

Matrix metalloproteinases (MMPs) is an enzyme required for cancer cells to metastasize/invade, and cancer cells with higher MMP activity have higher metastasis ability and progress quickly.

Story continues

In this study, Kazunori Kataoka of the Innovation Center of Nanomedicine, Kawasaki, Japan and colleagues created polymersomes (smart nanomachines) that act specifically in tissues that overproduce MMPs, prevent cancer metastasis, and developed a method to remove residual tumor tissue that could not be visually confirmed after surgery.

The scientists simultaneously loaded the cell division inhibitor colchicine and the MMP inhibitor marimastat into MMPs-responsive polymersomes as an enzymatically transformable nanomachine designed to achieve transformation following dePEGylation by cleavage of the inserted substrate peptide by MMPs. The effect on malignant tumors with high MMPs activity was evaluated.

During transformation, nanomachines with exposed guanidine residues easily penetrate into cells, and at the same time, by releasing the contained drugs, it exerts an anti-cancer effect.

Evaluating drug uptake using HT1080 cells derived from human fibrosarcoma that overproduce MMPs, studying pharmacokinetic and nano-bio interaction using a confocal laser scanning biomicroscope and evaluating metastasis inhibitory effect using triple-negative breast cancer transplantation model.

Reference

J. Li, Z. Ge, K. Toh, X. Liu, A. Dirisala, W. Ke, P. Wen, H. Zhou, Z. Wang, S. Xiao, J. F. R. Van Guyse, T. A Tockary, J. Xie, D. G.-Carter, H. Kinoh, S. Uchida, Y. Anraku, and K. Kataoka. Enzymatically Transformable Polymersome-Based Nanotherapeutics to Eliminate Minimal Relapsable Cancer. Advanced Materials, 2021.

DOI: 10.1002/adma.202105254

URL: https://onlinelibrary.wiley.com/doi/10.1002/adma.202105254https://tonomachi-ksf.kawasaki-net.ne.jp/pdf/pressrelease01.pdf

Events

Kawasaki Institute of Industrial Promotion exhibits at BioJapan 2021

The Kawasaki Institute of Industrial Promotion (KIIP) exhibited their booth at BioJapan 2021 between 13-15 October 2021 at PACIFICO Yokohama, Japan. BioJapan is one of Asia's major business partnering events and includes the three exhibitions of biotechnology (BioJapan), iPS technology (Regenerative Medicine JAPAN), and digital technology and life science (health TECH JAPAN).

BioJapan 2021 attracted approximately 900 companies from 25 countries and regions with 14,891 visitorsan increase of 1,104 from 2020.

https://jcd-expo.jp/en/

The Kawasaki Institute of Industrial Promotion (KIIP) established the Tonomachi KING SKYFRONT Cluster Division in April 2020 with the aim of further revitalizing R&D and business activities at KING SKYFRONT and creating a system for continuously creating innovation. By exhibiting at BioJapan, KIIP wants to raise awareness of KING SKYFRONT both within Japan and internationally, with the aim of matching and information gathering with an eye on future cooperation.

Summary of activities at BioJapan 2021

15 interviews with potential industrial partners and businesses

104 visitors to the KIIP booth

Approximately 200 exchanges of business cards

One interview with a local TV station (YouTV)

Further information

KING SKYFRONT https://www.king-skyfront.jp/en/ https://tonomachi-ksf.kawasaki-net.ne.jp/en/

About KING SKYFRONT

The Kawasaki INnovation Gateway (KING) SKYFRONT is the flagship science and technology innovation hub of Kawasaki City. KING SKYFRONT is a 40 hectare area located in the Tonomachi area of the Keihin Industrial Region that spans Tokyo and Kanagawa Prefecture and Tokyo International Airport (also often referred to as Haneda Airport).

KING SKYFRONT was launched in 2011 as a base for scholars, industrialists and government administrators to work together to devise real life solutions to global issues in the life sciences and environment.

Further information

KING-SKYFRONT iNewsletter Publishing TeamTONOMACHI LifeScience Cluster Division, Kawasaki Institute of Industrial Promotion Life Science & Environment research center (LiSE) 1F, 3-25-10, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa Prefecture, Japan, 210-0821Email: event-ksfcl@kawasaki-net.ne.jp

Kawasaki Institute of Industrial Promotion (KIIP)

Kawasaki Institute of Industrial Promotion was established in 1988 funded 100% from Kawasaki City for the purpose of coping with the hollowing out of industry and changes in the demand structure. In order to realize a higher level of market development, transforming R&D type companies, training technological capabilities to support it, human resources development, understanding market needs, etc., by utilizing the functions of the Kawasaki, KIIP has been contributing to revitalize the local economy by promoting exchanges of local industry information, advancing technology and corporate exchanges with establishment of a R&D institutions, developing creative human resources through workshops and promoting businesses such as expanding sales channels through exhibition business.

https://www.kawasaki-net.ne.jp/

Innovation Center of NanoMedicine (iCONM)

Innovation Center of NanoMedicine (iCONM) started its operation in April 2015 as a core research center in life science field at King SkyFront on the request of Kawasaki city that KIIP utilized national policies as a business operator and proposer. It is a unique research center that the world has ever seen which is designed for the purpose of promoting open innovation through industry-academia-government/medical-engineering collaboration, prepared with state-of-the-art facilities and experimental equipment, that enables comprehensive research and development from organic synthesis / microfabrication to preclinical testing.

iCONM: https://iconm.kawasaki-net.ne.jp/en/index.html

Center of Innovation Program (COI)

The COI program is a research and development program under the Ministry of Education, Culture, Sports, Science and Technology and the Japan Science and Technology Agency. The program employs the backcasting approach and set interdisciplinary and collaborative R&D themes that should be challenged at the present from the issues that are underlying in the future society. Eighteen centers have been established nationwide to realize radical innovation through industry-academia collaboration which cannot be accomplished by industry and academia alone.

The Kawasaki center is the only COI center managed by local governments, not universities, and the research projects carried out there are called COINS (Center of Open Innovation Network for Smart Health).

COI: https://www.jst.go.jp/tt/EN/platform/coi.html COINS: https://coins.kawasaki-net.ne.jp/en/

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/latest-updates-on-the-research-activities-at-king-skyfront-japan-301411814.html

SOURCE KING SKYFRONT

Read the rest here:
Latest updates on the research activities at KING SKYFRONT, Japan. - Yahoo Finance

Nanomedicine Market Overview 2021: Current Trends And Future Aspect Analysis 2030 The Host – The Host

Posted on October 31, 2021 by Prof Baldwin

Overview:

Nanomedicineis an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 11,000 nm range, biochips, and polymer therapeutics.

Majority of nanomedicines prescribedcurrently, allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and bloodbrain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/9807

Market Analysis:

The Global Nanomedicine Market is estimated to witness a CAGR of 17.1% during the forecast period 20172023. The nanomedicine market is analyzed based on two segments therapeutic applications and regions.

The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.

Regional Analysis:

The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.

Therapeutic Application Analysis:

Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.

Key Players:

Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.

Competitive Analysis:

Place a Direct Purchase Order @https://www.trendsmarketresearch.com/checkout/9807/Single

At present, the nanomedicine market is at a nascent stage but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits:

The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical players initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Request for Report Discount:https://www.trendsmarketresearch.com/report/discount/9807

Original post:
Nanomedicine Market Overview 2021: Current Trends And Future Aspect Analysis 2030 The Host - The Host

Get Huge Discount on Nanomedicine Market by Forecast to 2026 with Profiling Top Players GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck…

Posted on June 11, 2021 by Prof Baldwin

Global Nanomedicine Market Report is recently published by Reports N Markets is a value addition to the studied Market. The compilation of the research report is conditioned by primary and secondary research techniques. The report also elaborates on factors that are fueling or hampering the growth of the current Global Nanomedicine Market. It focuses on recent trends and technologies that boost company performance. It also offers a panoramic view of the competitive landscape that will aid in differentiating competition at global and national level. To approximate risks and challenges involved, various business models have been presented.

Download Sample Copy of this Report: https://www.reportsnmarkets.com/request_sample.php?id=97555&mode=hbs

It enumerates the financial aspects of the businesses such as profit margin, gross margin, market shares, and pricing structures. Business profiles of several top-level industries have been examined to get a clear idea about the successful strategies followed by them. The report is rich with illustrations like infographics, charts, tables, and pictures to generate a strong footing for detailed analysis of recent trends and technological advancements in the Global Nanomedicine Market.

Market Segment as follows:

Product Type Segmentation Includes

Regenerative Medicine

In-vitro & In-vivo Diagnostics

Vaccines

Drug Delivery

Application Segmentation Includes

Clinical Cardiology

Urology

Genetics

Orthopedics

Ophthalmology

Companies Includes

GE Healthcare

Johnson & Johnson

Mallinckrodt plc

Merck & Co. Inc.

Nanosphere Inc.

Pfizer Inc.

Sigma-Tau Pharmaceuticals Inc.

Smith & Nephew PLC

Stryker Corp

Teva Pharmaceutical Industries Ltd.

UCB (Union chimique belge) S.A

Get Best Discount on this Report: https://www.reportsnmarkets.com/ask_for_discount.php?id=97555&mode=hbs

Table of Contents

Chapter 1 Global Nanomedicine Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Nanomedicine Market Competition by Companies

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Nanomedicine Market Analysis by Application

Chapter 8 Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Global Nanomedicine Market Effect Factors Analysis

Chapter 12 Global Nanomedicine Market Forecast

For More Information: https://www.reportsnmarkets.com/enquiry_before_buying.php?id=97555&mode=hbs

Reports N Markets,

125 High Street, Boston, MA 02110

sales@reportsnmarkets.com

https://www.reportsnmarkets.com

+1 617 671 0092

Updating the PLOS ONE Nanomaterials Collection Author Perspectives, Part 3 – EveryONE – PLoS Blogs

Posted on September 3, 2021 by Prof Baldwin

In July, we updated our Nanomaterials Collection, featuring papers published over the past few years in PLOS ONE. This collection showcases the breadth of the nanomaterials community at PLOS ONE, and includes papers on a variety of topics, such as the fabrication of nanomaterials, nanomaterial-cell interactions, the role of nanomaterials in drug delivery, and nanomaterials in the environment.

To celebrate this updated collection, we are conducting a series of Q&As with authors whose work is included in the collection. Next out is our conversations with Roberto Vazquez-Muoz from the University of Connecticut Health Center, Roselyne Ferrari from Universit de Paris and Yerol Narayana from Mangalore University. They discuss the future potential of nanomaterials research, the value of open science practices, and their experiences of pursuing unexpected effects seen in the lab. We will be adding more author interviews over the next few weeks, so please do keep checking back.

Roberto Vazquez-Muoz University of Connecticut Health Center

Currently, I work at the University of Connecticut Health Center (UConn Health), USA. Im a nanomedicine scientist with a multidisciplinary background: B.Sc. with a concentration in Biology, with postgraduate education in Microbiology (M. Sc.) and Nanotechnology (Ph.D.). My research focuses on the complex systems interactions between antimicrobial nanomaterials (nanoantibiotics), microbial cells (pathogens and probiotics), antibiotics, and the environment. My goal is to develop affordable, novel nanotechnology-based solutions to combat multidrug-resistant infectious diseases, particularly for communities under limited resources. My network includes international and transdisciplinary research teams to develop applied nanotechnology solutions for the agricultural, veterinary, and clinical sectors. My work has been published in international peer-reviewed journals, and I have developed patented and commercial products. Ive been awarded by different institutions such as The Ensenada Center for Scientific Research and Higher Education (Mexico), Rotary Internationals Rotaract, the International Network of Bionanotechnology, and the New England I-Corps (MIT)/Accelerate (UCONN) program.

Roberto Vazquez-Muozs paper in the Nanomaterials Collection: Vazquez-Muoz R, Meza-Villezcas A, Fournier PGJ, Soria-Castro E, Juarez-Moreno K, Gallego-Hernndez AL, et al. (2019) Enhancement of antibiotics antimicrobial activity due to the silver nanoparticles impact on the cell membrane. PLoS ONE 14(11): e0224904. https://doi.org/10.1371/journal.pone.0224904

What motivated you to work in this field?

RVM: My motivation to work in this field comes from my interest in the impact of infectious diseases through history and our ability to create solutions to combat them. This interest led me to focus on the interactions between nanomaterials, microbial cells, and antimicrobial substances for combat infection. Additionally, as current treatments are less and less effective against pathogens, nanotechnology has proven to be an effective strategy to fight the crisis of infectious diseases.

Nanomaterials research has increased in popularity over the past few years as a research topic. Do you envision that the field can continue to grow this way, and do you see any challenges on the horizon?

RVM: Yes, nanomaterials research has increased in popularity worldwide, and we have seen exponential growth in publications. The field will continue to grow for years as we constantly discover nanomaterials novel structures, properties, and applications. Additionally, we continuously develop novel synthesis methods and understand the interactions between nanomaterials and other systems (organisms, materials, environment, etc.).

However, there are several challenges on the horizon. A critical challenge is understanding the impact of nanomaterials on living organisms and the environment. It is crucial to expand the research on human and ecological nanotoxicology and the fate of nano-waste on the environment. Another challenge is the standardization of research data. As nanomaterials research is a multidisciplinary field, there is still a lack of standard criteria for conducting and publishing research, leading to difficulties in comparing data from different studies.

Can you tell us about an experience during your research, whether in the lab or at the computer or in conversation etc., where something finally clicked or worked?

RVM: One of my experiences during my research is when I was working on how nanomaterials increase the antibacterial activity of antibiotics. Different published studies showed the impact of nanomaterials on cell structure and metabolism. At the same time, other studies reported synergistic or antagonistic activity between nanomaterials and antibiotics; however, their explanations about the mechanisms were primarily theoretical. Unfortunately, there was no apparent connection between the proposed mechanisms and the synergistic activity reported by other groups. To fill that knowledge gap, we conducted experimental work to evaluate the physical and chemical interactions in the nanomaterials-antibiotics-microbial cell complex system. Then, when we compared our data with the literature, we started to see the connecting dots that could explain the synergistic activity of antibiotics. Moreover, our model could also explain some results published from other groups. That project was a stimulating and satisfactory experience and contributed to a better understanding of the synergistic activity of nanoparticles with antibiotics.

Is there a specific research area where a collaboration with the nanomaterials community could be particularly interesting for interdisciplinary research?

RVM: There are many research areas where interdisciplinary and transdisciplinary collaboration with the nanomaterials community is exciting. Nanomedicine is my first pick. The novel properties of nanomaterials have raised a lot of interest from the medical community, particularly for drug delivery, controlled release, reducing toxicity, among others. Additionally, beyond treatments, the development of new instrumentation, biosensors, analytical kits, sanitizing formulations, and other related applications for the healthcare sector is on the rise, creating more opportunities to work in diverse, interdisciplinary environments. In this regard, I have an interdisciplinary background (microbiology and nanotechnology), and my work focuses on medical applications, which allows me to participate in different research groups.

Roselyne Ferrari Universit de Paris

I am an Associate Professor in the Paris Diderot University (now Universit de Paris) since 1994. I defended my PhD thesis entitled Investigation of foliar lipid peroxidation in higher plants and evaluation of antioxidant capacities of sensitive or drought-resistant plants in 1992 (Paris Diderot University, France) in the field of Tropical Plant Biology. I then got interested in microorganisms and studied a class of enzymes capable of detoxifying fatty acid hydroperoxides: the alkylhydroperoxide reductases. I then investigated the ability of Escherichia coli to detoxify emerging pollutants in aquatic environments and in particular man-made metal oxide nanoparticles. I participated for 10 years in the development of laboratory tests to assess the toxicity of zinc oxide and titanium nanoparticles in natural aquatic environments. I showed, through metabolomics and proteomics, that E. coli tries to overcome the stress caused by nanoparticles by increasing its oxidative and respiratory capacity. More recently, I started to work again on polyunsaturated fatty acids and peroxidation phenomena, but this time on fungi. Recently I am also interested in the ability of some microscopic coprophilous fungi to destroy lignocellulose. These ascomycete fungi are over-equipped with hydrolytic enzymes, such as oxidases or oxygenases.

Roselyne Ferraris paper in the Nanomaterials Collection: Planchon M, Lger T, Spalla O, Huber G, Ferrari R (2017) Metabolomic and proteomic investigations of impacts of titanium dioxide nanoparticles on Escherichia coli. PLoS ONE 12(6): e0178437. https://doi.org/10.1371/journal.pone.0178437

What is your favorite thing about nanomaterials?

RF: I am interested in the toxicology of nanoparticles in the environment and more particularly in their dissemination in the 3 compartments (soil water air). I am also interested in the fixation of environmental metal oxide nanoparticles by the bark of urban trees.

Have you had any surprises in your research recently, where the result was not what you expected?

RF: I did indeed have some surprises in the results I got in the paper I published in PLOS ONE. I did not expect that the amount of ATP would increase in Escherichia coli bacteria after they were brought into contact with the titanium dioxide nanoparticles. Unfortunately I did not pursue this line of research and I remain on this question.

Did you have to adapt your work in light of the pandemic, and if so, how?

RF: I adapted like many researchers and continued my work following the recommendations of my University.

What do you see as the greatest opportunities for disseminating research in your field, or for communicating science in general?

RF: Social networks, media in general have allowed us to continue to disseminate to our fellow researchers as well as video conferencing.

Yerol Narayana Mangalore University

Obtained MSc and PhD from Mangalore University. Presently the Professor and Chairman, Board of Studies, Department of Physics of Mangalore University. Area of research include Environmental Radioactivity, Radiation Biophysics and Nanoparticles for Biomedical Applications. Published more than 150 research papers in International Journals and presented more than 250 research papers in conferences. Completed five major research projects and one major research project is ongoing. Guided 13 students for PhD degree and 8 students are currently working for their PhD degree. Received Commonwealth Fellowship Award for Post-Doctoral research in the United Kingdom during 2000-2001, Wington Tiular Fellowship award from ACU in 2013, Dr A K Ganguly Award from Indian Association for Radiation Protection, India in 2016, Best Teacher Award from Mangalore University in the year 2017 and Best Research Publication Award from Govt. of Karnataka, India, in 2019.

Yerol Narayanas paper in the Nanomaterials Collection: Suvarna S, Das U, KC S, Mishra S, Sudarshan M, Saha KD, et al. (2017) Synthesis of a novel glucose capped gold nanoparticle as a better theranostic candidate. PLoS ONE 12(6): e0178202. https://doi.org/10.1371/journal.pone.0178202

What route did you take to where you currently are in your career?

YN: I obtained my Masters degree in physics from, Mangalore University in 1989 and PhD degree from the same University in 1994. I joined the Physics Department of Mangalore University in 1995 as Assistant Professor and subsequently became Professor in 2010. I have done my Post-doctoral research at BGS, UK during 2000-01 under the commonwealth fellowship and subsequently at University of Stirling, UK in 2014 under Wighton-Titular Fellowship. Currently I am working as Professor of Physics at Mangalore University.

How important are open science practices in your field? Do you have any success stories from your own research of sharing or reusing code, data, protocols, open hardware, interacting with preprints, or something else?

YN: Open science practices are very useful in any field of scientific research. In my field, open access to published scientific materials have helped in a big way in designing experiments, data analysis and furtherance of research.

If you could dream really big, is there a particular material, function or material property that seems far away at the moment, but you think could be attained in the future?

YN: At present the major challenge in Radiotherapy is the radio-resistance of tumor cells and protecting the normal cells. Researchers are working on a concept of multiple therapy i.e. simultaneous chemotherapy, immunotherapy, hyperthermia therapy and radiotherapy to overcome the radio-resistance and it has been proved to be effective. Live tumor imaging is another big challenge. Some nanoparticles have shown potential to improve the aforesaid individual treatment and imaging techniques. At present, individual nanomaterials are being tried for treatment and imaging. The usage of multiple nanomaterials simultaneously would not be safe as their unique interaction mechanism may create unforeseen problems. Therefore, we need a single nanomaterial that is capable of supporting multiple therapy and live imaging to reduce the side effects and to assure safety. We believe that it will be a reality in the near future.

Disclaimer: Views expressed by contributors are solely those of individual contributors, and not necessarily those of PLOS.

Featured image: http://dx.doi.org/10.1371/journal.pone.0133088

See the article here:
Updating the PLOS ONE Nanomaterials Collection Author Perspectives, Part 3 - EveryONE - PLoS Blogs

Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicine-Specific Cancer Targeting…

Posted on May 31, 2021 by Prof Baldwin

This article was originally published here

Chem Rev. 2021 May 26. doi: 10.1021/acs.chemrev.1c00009. Online ahead of print.

ABSTRACT

RNA nanotechnology is the bottom-up self-assembly of nanometer-scale architectures, resembling LEGOs, composed mainly of RNA. The ideal building material should be (1) versatile and controllable in shape and stoichiometry, (2) spontaneously self-assemble, and (3) thermodynamically, chemically, and enzymatically stable with a long shelf life. RNA building blocks exhibit each of the above. RNA is a polynucleic acid, making it a polymer, and its negative-charge prevents nonspecific binding to negatively charged cell membranes. The thermostability makes it suitable for logic gates, resistive memory, sensor set-ups, and NEM devices. RNA can be designed and manipulated with a level of simplicity of DNA while displaying versatile structure and enzyme activity of proteins. RNA can fold into single-stranded loops or bulges to serve as mounting dovetails for intermolecular or domain interactions without external linking dowels. RNA nanoparticles display rubber- and amoeba-like properties and are stretchable and shrinkable through multiple repeats, leading to enhanced tumor targeting and fast renal excretion to reduce toxicities. It was predicted in 2014 that RNA would be the third milestone in pharmaceutical drug development. The recent approval of several RNA drugs and COVID-19 mRNA vaccines by FDA suggests that this milestone is being realized. Here, we review the unique properties of RNA nanotechnology, summarize its recent advancements, describe its distinct attributes inside or outside the body and discuss potential applications in nanotechnology, medicine, and material science.

PMID:34038115 | DOI:10.1021/acs.chemrev.1c00009

Covid-19 Impact Analysis on Nanomedicine Market by Forecast to 2026 with Profiling Top Players GE Healthcare, Johnson & Johnson, Mallinckrodt…

Posted on June 11, 2021 by Prof Baldwin

Download Sample Copy of this Report: https://www.reportsnmarkets.com/request_sample.php?id=97555&utm_source=Blog&utm_medium=HS

Market Segment as follows:

Product Type Segmentation Includes

Regenerative Medicine

In-vitro & In-vivo Diagnostics

Vaccines

Drug Delivery

Application Segmentation Includes

Clinical Cardiology

Urology

Genetics

Orthopedics

Ophthalmology

Companies Includes

GE Healthcare

Johnson & Johnson

Mallinckrodt plc

Merck & Co. Inc.

Nanosphere Inc.

Pfizer Inc.

Sigma-Tau Pharmaceuticals Inc.

Smith & Nephew PLC

Stryker Corp

Teva Pharmaceutical Industries Ltd.

UCB (Union chimique belge) S.A

Get Best Discount on this Report: https://www.reportsnmarkets.com/ask_for_discount.php?id=97555&utm_source=Blog&utm_medium=HS

Table of Contents

Chapter 1 Global Nanomedicine Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Nanomedicine Market Competition by Companies

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Nanomedicine Market Analysis by Application

Chapter 8 Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Global Nanomedicine Market Effect Factors Analysis

Chapter 12 Global Nanomedicine Market Forecast

For More Information: https://www.reportsnmarkets.com/enquiry_before_buying.php?id=97555&utm_source=Blog&utm_medium=HS

Reports N Markets,

125 High Street, Boston, MA 02110

sales@reportsnmarkets.com

https://www.reportsnmarkets.com

+1 617 671 0092

See the rest here:
Covid-19 Impact Analysis on Nanomedicine Market by Forecast to 2026 with Profiling Top Players GE Healthcare, Johnson & Johnson, Mallinckrodt...

Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MNDResults provide…

Posted on December 13, 2020 by Prof Baldwin

SALT LAKE CITY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of blinded interim results from the Phase 2 RESCUE-ALS clinical trial investigating the effects of its lead clinical candidate, CNM-Au8, for the treatment of amyotrophic lateral sclerosis (ALS). CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals with catalytic activity that has been shown to enhance the metabolic energetic capacity of motor neurons while simultaneouslyreducing oxidative stress.

As of the data cutoff (October 27, 2020), the trial was fully enrolled with a preliminary blinded assessment of the studys primary endpoint, the motor neuron number index-4 [MUNIX(4)] score, showing that more than 40% of enrolled patients with completed week 12 data experienced improvements in motor neuron function assessed by MUNIX. When compared to baseline values, the average MUNIX(4) score of the overall trial population (including both active CNM-Au8 and placebo) experienced an absolute increase in mean MUNIX(4) values. This increase exceeded the expectations of the statistical modeling on which the study was based, which predicted a linear decline in average MUNIX(4) score from study onset (Neuwirth et al. JNNP 2015). These data, while blinded, suggest that CNM-Au8 may have neuro-reparative potential in ALS patients. Clene expects to report the complete, unblinded results from the RESCUE-ALS study in 2H 2021.

Although blinded to treatment assignment, these data are encouraging. We believe Clenes breakthrough approach with the application of physics to biology via direct electron interactions within cellular systems at the nano-scale may hold the potential to revolutionize the treatment of neurodegenerative diseases such as ALS and other motor neuron diseases, said Robert Glanzman, MD, FAAN, Chief Medical Officer of Clene.

Rob Etherington, President and CEO of Clene added, This blinded interim analysis suggests that CNM-Au8 is working mechanistically to address a foundational challenge common to many neurodegenerative diseases, namely that stressed or failing neurons need additional energy for their survival, repair, and improved function. Emerging MUNIX data potentially indicate preservation of motor units, which is promising. We eagerly anticipate final results and are encouraged that these blinded interim results may provide hope for ALS patients and their families as they search for new therapies to treat this devastating disease.

The presentation (CLT-23) titled, RESCUE-ALS Trial, A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in Amyotrophic Lateral Sclerosis Patients: Design and Interim Blinded Results, is available as a live e-Poster on December 10th at 12:10 12:50 pm EST at the Virtual 31st International Symposium on ALS/MND, held online (https://symposium.mndassociation.org/virtual-2020/).

About RESCUE-ALSRESCUE-ALS is a Phase 2 multi-center, randomized, double-blind, parallel group, placebo-controlled study examining the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in participants who are newly symptomatic with ALS (within 24-months of screening or 12-months from diagnosis). Enrolled subjects will be randomized 1:1 to receive either active treatment with CNM-Au8 (30 mg) or placebo in addition to their current standard of care. Participants will receive their randomized treatment over 36 consecutive weeks during the treatment period. The objective of this study is to assess the impact of improving neuronal bioenergetics, reducing reactive oxygen species and promoting protein homeostasis with CNM-Au8 to slow disease progression in patients with ALS. In the trial, efficacy is assessed as the average change in motor neuron unit number index (MUNIX) estimated by electromyography for the abductor digiti minimi (ADM), abductor pollicis brevis (APB), biceps brachii (BB), and tibialis anterior (TA) (muscles of the hand, arm, and leg). The trial was fully enrolled with 44 participants as of the reported 27-October-2020 data cut. Baseline characteristics include [mean (SD)], MUNIX(4) score: 93.7 (45.8); FVC % predicted: 80.8 (16.3); ALSFRS-R: 38.6 (6.1); ALSSQOL-20: 3.3 (1.3), mean time from diagnosis: 4.7 (4.6) months; riluzole background treatment, 92%.

About CNM-Au8CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted gold nanocrystals that act catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of pure gold nanoparticles, composed of clean-surfaced, faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteers and has shown both remyelination and neuroprotective effects in multiple preclinical (animal) models. Preclinical data, both published in peer-reviewed journals and presented at scientific congresses, demonstrate that treatment of neuronal cultures with CNM-Au8 improves survival of neurons, protects neurite networks, decreases intracellular levels of reactive oxygen species and improves mitochondrial capacity in response to cellular stresses induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in rodent models of ALS, multiple sclerosis, and Parkinsons disease versus vehicle (placebo). CNM-Au8 is currently being tested in a Phase 2 clinical study for the treatment of chronic optic neuropathy in patients with MS in addition to Phase 2 and Phase 3 clinical studies for disease progression in patients with ALS.

About ALSALS is a universally fatal neurodegenerative disorder that results in loss of motor neurons in the cerebral cortex, brain stem, and spinal cord. ALS, also known as Lou Gehrig's disease, leads to the death of the neurons controlling voluntary muscles resulting in weakness, muscle atrophy, and progressive paralysis. ALS affects more than 15,000 patients in the United States and is the most prevalent adult-onset progressive motor neuron disease.

About CleneClene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.

Forward-Looking StatementsThis press release contains, and certain oral statements made by representatives of Tottenham, Clene, and their respective affiliates, from time to time may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Tottenham's and Clene's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Tottenham's and Clene's expectations with respect to future performance and anticipated financial impacts of the business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Tottenham or Clene and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed business combination; (2) the outcome of any legal proceedings that may be instituted against Tottenham or Clene following the announcement of the Merger Agreement and the transactions contemplated therein; (3) the inability to complete the business combination, including due to failure to obtain approval of the shareholders of Tottenham or other conditions to closing in the Merger Agreement; (4) delays in obtaining or the inability to obtain necessary regulatory approvals (including approval from regulators, as applicable) required to complete the transactions contemplated by the Merger Agreement; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement or could otherwise cause the transaction to fail to close; (6) the inability to obtain or maintain the listing of the post-acquisition company's ordinary shares on NASDAQ following the business combination; (7) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; (8) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the business combination; (10) changes in applicable laws or regulations; (11) the possibility that Clene or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties to be identified in the Form S-4 filed by Chelsea Worldwide (when available) relating to the business combination, including those under "Risk Factors" therein, and in other filings with the Securities and Exchange Commission (SEC) made by Tottenham and Clene. Tottenham and Clene caution that the foregoing list of factors is neither exclusive nor exhaustive. Tottenham and Clene caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Tottenham or Clene undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Media ContactAndrew MielachLifeSci Communications(646) 876-5868amielach@lifescicomms.com

Investor ContactBruce MackleLifeSci Advisors, LLC(929) 469-3859bmackle@lifesciadvisors.com

See original here:
Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MNDResults provide...

Resveratrol and prostate cancer: the power of phytochemicals – DocWire News

Posted on December 30, 2020 by Prof Baldwin

This article was originally published here

Curr Med Chem. 2020 Dec 28. doi: 10.2174/0929867328666201228124038. Online ahead of print.

ABSTRACT

Prostate cancer is the fifth cause of tumor-related deaths in man worldwide. Due to its long latency period, this pathology represents an ideal type of disease for chemopreventive studies. Among the drugs considered thus far for the treatment of prostate cancer, the natural compound resveratrol emerged as very promising. Resveratrol is a widely recognized as chemopreventive agent and was shown to potentiate the antitumor activity of conventional chemotherapeutics in several tumors, including prostate cancer. Here we overview the literature of the last five years and summarize the recent achievements of resveratrol and its derivatives as antimetastatic agents in prostate cancer. Moreover, drug combination studies as well as nanomedicine approaches proposed to improve resveratrol activity and to overcome delivery drawbacks are addressed. The last part of the review discusses the clinical trials containing resveratrol ongoing on cancer patients.

PMID:33371831 | DOI:10.2174/0929867328666201228124038

View original post here:
Resveratrol and prostate cancer: the power of phytochemicals - DocWire News

Application of Nanotechnology in the COVID-19 Pandemic | IJN – Dove Medical Press

Posted on January 27, 2021 by Prof Baldwin

Dongki Yang

Department of Physiology, College of Medicine, Gachon University, Incheon, 21999, South Korea

Correspondence: Dongki YangDepartment of Physiology, College of Medicine, Gachon University, Incheon 21999, South KoreaTel +82-32-899-6072Fax +82-32-899-6588Email dkyang@gachon.ac.kr

Abstract: COVID-19, caused by SARS-CoV-2 infection, has been prevalent worldwide for almost a year. In early 2000, there was an outbreak of SARS-CoV, and in early 2010, a similar dissemination of infection by MERS-CoV occurred. However, no clear explanation for the spread of SARS-CoV-2 and a massive increase in the number of infections has yet been proposed. The best solution to overcome this pandemic is the development of suitable and effective vaccines and therapeutics. Fortunately, for SARS-CoV-2, the genome sequence and protein structure have been published in a short period, making research and development for prevention and treatment relatively easy. In addition, intranasal drug delivery has proven to be an effective method of administration for treating viral lung diseases. In recent years, nanotechnology-based drug delivery systems have been applied to intranasal drug delivery to overcome various limitations that occur during mucosal administration, and advances have been made to the stage where effective drug delivery is possible. This review describes the accumulated knowledge of the previous SARS-CoV and MERS-CoV infections and aims to help understand the newly emerged SARS-CoV-2 infection. Furthermore, it elucidates the achievements in developing COVID-19 vaccines and therapeutics to date through existing approaches. Finally, the applicable nanotechnology approach is described in detail, and vaccines and therapeutic drugs developed based on nanomedicine, which are currently undergoing clinical trials, have presented the potential to become innovative alternatives for overcoming COVID-19.

Keywords: COVID-19, SARS-CoV-2, antiviral drug, vaccines, nanoparticles, nanotechnology

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original here:
Application of Nanotechnology in the COVID-19 Pandemic | IJN - Dove Medical Press

Healthcare Nanotechnology (Nanomedicine) Market 2020 with Growth, Share, Demand, Global Production with Revenue Share, and Applications Forecast to…

Posted on October 29, 2020 by Prof Baldwin

Healthcare Nanotechnology (Nanomedicine) Market report delivers an overview of the market trends, drivers, and barriers with respect to the competitive landscape. It also provides a detailed overview of the market of different regions globally.Furthermore, the Healthcare Nanotechnology (Nanomedicine) market report contains a primary overview of the Healthcare Nanotechnology (Nanomedicine) market covering different product definitions, classifications, and participants in the industry chain structure.

The global Healthcare Nanotechnology (Nanomedicine) market provides quantitative and qualitative analysis of the competitive landscape, development trends, and key success in the Healthcare Nanotechnology (Nanomedicine) industry.

Competitor Landscape: Healthcare Nanotechnology (Nanomedicine) market report contains top companies on the basis of types, applications, size, share, and regions.

Inquire or Share Your Questions If Any Before the Purchasing This Report https://www.industryresearch.co/enquiry/pre-order-enquiry/14099195

Key Market Trends:

The Growth of Nanomedicine is Expected to Provide High Opportunities for the Treatment of Neurological Diseases, Over the Forecast Period

A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. Recent years observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others, opens up the necessity of nanomedicine with stem cell therapy. Some of the registered nanoparticles for the complex CNS treatment are a gold nanoparticle, lipid nanoparticle, and chitosan nanoparticles.

Other than neurological diseases, research-based progress was found in the treatment of cancers, with the scientific communities identifying new metabolic pathways to find better drug combination using nanomedicine.

North America is Expected to Hold the Largest Share in the Market

In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy. In the United States, the National Nanotechnology Initiative (NNI), which was initiated in 2000, is among the supreme bodies that manage all nanotechnology-related activities. Under the NNI, several agencies are working in collaboration with companies and universities. For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs were developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Thus, most of the companies are investing in R&D. Nanotechnology is likely to play a significant role in the delivery of drugs. In the recent strategic plan presented by the NNI in 2016, several programs were identified to further advance the research and development programs, over the forecast period.

Reason to buy Healthcare Nanotechnology (Nanomedicine) Market Report:

Purchase this Report (Price 4250 USD for a Single-User License) https://www.industryresearch.co/purchase/14099195

Detailed TOC of Healthcare Nanotechnology (Nanomedicine) Market 2020-2024:

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases4.2.2 Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures4.2.3 Growing Preference for Personalized Medicines4.3 Market Restraints4.3.1 High Cost4.3.2 Stringent Regulations for Commercial Introduction4.4 Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 By Application5.1.1 Drug Delivery5.1.2 Biomaterials5.1.3 Active Implants5.1.4 Diagnostic Imaging5.1.5 Tissue Regeneration5.1.6 Other Applications5.2 By Disease5.2.1 Cardiovascular Diseases5.2.2 Oncological Diseases5.2.3 Neurological Diseases5.2.4 Orthopedic Diseases5.2.5 Infectious Diseases5.2.6 Other Diseases5.3 Geography5.3.1 North America5.3.1.1 US5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 France5.3.2.2 Germany5.3.2.3 UK5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle East & Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle East & Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Sanofi SA6.1.2 Celegene Corporation6.1.3 CytImmune Sciences Inc.6.1.4 Johnson & Johnson6.1.5 Luminex Corporation6.1.6 Merck & Co. Inc.6.1.7 Nanobiotix6.1.8 Pfizer Inc.6.1.9 Starpharma Holdings Limited6.1.10 Taiwan Liposome Company Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Hyoscine-N-Butyl Bromide Market Size and Share Outlook 2020 to 2026 | Key Developments Trends, Growth Factors, Business Status and Regional Analysis

Property Management System in Hotel Market Growth Share 2020 Regional Trends, Market Overview with Key Players, Industry Size, Demand Status Forecast to 2025 | Report by Industry Research.co

Wood Ceilings Market Share and Business Development 2020 Future Plans of Top Companies, Growth Size, Industry Share by Latest Trends Forecast to 2025

PBT Engineering Plastics Market Growth Opportunities by Key Players 2020 | Evolving Technologies, Market Dynamics, Global Size, Industry Share Analysis till 2026 Report by Industry Research.co

Ethylene Methacrylic Acid (EMA) Market Size, Share, Top Manufacturers 2020 Future Growth Rate, Industry Trends, Business Strategy, Demand Status by 2026 With COVID-19 Analysis

Rangefinders Market Growth Factors by Latest Developments 2020 | Future Demand Status, Business Strategies, Opportunities, Trends, Industry Size and Share Forecast to 2026

IVF Devices and Consumables Market 2020 | by Growing Factors, Size, Global Opportunities by Leading Players, Top Countries Data, Demand Status, Regional Overview by CAGR Value, and Share Analysis till 2026

Dental Carts Market Size Analysis by Latest Trends 2020 | Global Industry Growth Factors, Revenue, CAGR Status, Leading Key Players Update, Business Share by Regions Forecast to 2026

Epigenetics Drugs and Diagnostic Technologies Market Size by Growth Scenario 2020 Trend Analysis, Industry Status by Manufacturers, Business Share, Future Scope and Global Opportunities Forecast to 2026

Deep Brain Stimulation (DBS) Devices Market Size, Share Analysis 2020 Global Analysis by Key Players, Growth Overview, Type and Applications by Regions Forecast to 2025 | Industry Research.co

Cholesterol Lowering Biologic Drugs Market Size by Future Scope 2020 | Global Industry Revenue, Share, Future Demand Status, Growth Segmentations Analysis by Regions Forecast to 2026

Beeswax Market Growth Share 2020 Regional Trends, Market Overview with Key Players, Industry Size, Demand Status Forecast to 2025 | Report by Industry Research.co

Read the rest here:
Healthcare Nanotechnology (Nanomedicine) Market 2020 with Growth, Share, Demand, Global Production with Revenue Share, and Applications Forecast to...

Global Nanomedicine Market Analysis and Forecast to 2025 by Cancer Detection, Monitoring Therapy & Disease Detection – ResearchAndMarkets.com -…

Posted on December 13, 2020 by Prof Baldwin

The "Nanomedicine Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarkets.com's offering.

This report describes the global market size of Nanomedicine from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025. For the geography segment, regional supply, demand, major players, price is presented from 2015 to 2025.

For the competitor segment, the report includes global key players of Nanomedicine as well as some small players.

The information for each competitor includes:

Company Profile

Main Business Information

SWOT Analysis

Sales, Revenue, Price and Gross Margin

Market Share

Applications Segment:

Cancer Detection

Monitoring Therapy

Disease Detection

Companies Covered:

Abbott Laboratories

Cepheid

Philips

GE Healthcare

Siemens

Gen-Proberporated

MDxHealth SA

EpiGenomics AG

Roche Diagnostics

Sequenom

Manhattan Scientifics

Key Topics Covered:

Chapter 1 Executive Summary

Chapter 2 Abbreviation and Acronyms

Chapter 3 Preface

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter 4 Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End-users

Chapter 5 Market Trend Analysis

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

Chapter 6 Industry Chain Analysis

6.1 Upstream/Suppliers Analysis

6.2 Nanomedicine Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End-users

Chapter 7 Latest Market Dynamics

7.1 Latest News

7.2 Merger and Acquisition

7.3 Planned/Future Project

7.4 Policy Dynamics

Chapter 8 Trading Analysis

8.1 Export of Nanomedicine by Region

8.2 Import of Nanomedicine by Region

8.3 Balance of Trade

Chapter 9 Historical and Forecast Nanomedicine Market in North America (2015-2025)

9.1 Nanomedicine Market Size

9.2 Nanomedicine Demand by End Use

Story continues

9.3 Competition by Players/Suppliers

9.4 Type Segmentation and Price

9.5 Key Countries Analysis

9.5.1 US

9.5.2 Canada

9.5.3 Mexico

Chapter 10 Historical and Forecast Nanomedicine Market in South America (2015-2025)

10.1 Nanomedicine Market Size

10.2 Nanomedicine Demand by End Use

10.3 Competition by Players/Suppliers

10.4 Type Segmentation and Price

10.5 Key Countries Analysis

10.5.1 Brazil

10.5.2 Argentina

10.5.3 Chile

10.5.4 Peru

Chapter 11 Historical and Forecast Nanomedicine Market in Asia & Pacific (2015-2025)

11.1 Nanomedicine Market Size

11.2 Nanomedicine Demand by End Use

11.3 Competition by Players/Suppliers

11.4 Type Segmentation and Price

11.5 Key Countries Analysis

11.5.1 China

11.5.2 India

11.5.3 Japan

11.5.4 South Korea

11.5.5 Asean

11.5.6 Australia

Chapter 12 Historical and Forecast Nanomedicine Market in Europe (2015-2025)

12.1 Nanomedicine Market Size

12.2 Nanomedicine Demand by End Use

12.3 Competition by Players/Suppliers

12.4 Type Segmentation and Price

12.5 Key Countries Analysis

12.5.1 Germany

12.5.2 France

Nanomedicine Market 2019 by Rising-Trends, Growth Analysis, Industry Share, Product Types, User-Demand, Business Strategy and Comprehensive Valuation…

Posted on July 23, 2020 by Prof Baldwin

A new intelligence report Nanomedicine Market Was recently added to Nanomedicine Market Research collection of top-line market study reports. International Nanomedicine Market report is a meticulous all-inclusive analysis of this market that provides access to direct firsthand insights on the growth trail of market at near term and long term. On the grounds of factual advice sourced from authentic industry pros and extensive primary business study, the report offers insights about the historical growth pattern of Nanomedicine Market and present market situation. It then provides brief and long-term market growth projections.

Projections are only based on the comprehensive analysis of key Market dynamics that are expected to influence Nanomedicine Market performance and also their seriousness of impacting market growth within the span of assessment interval.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2734725&source=atm

In addition to evaluation of dynamics, the report supplies In-depth examination of key business trends that are anticipated to behave more prominently in global Nanomedicine Market. The study also provides valued information concerning the present and upcoming growth opportunities in Nanomedicine Market the important players and new market entrants can capitalize on.

Competitive Businesses And manufacturers in global market

segment by Type, the product can be split intoQuantum dotsNanoparticlesNanoshellsNanotubesNanodevicesMarket segment by Application, split intooncologyInfectious diseasesCardiologyOrthopedicsOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2734725&source=atm

Opportunity assessment offered in this Nanomedicine Market report Is important in terms of understanding the lucrative regions of investment, which prove to be the actionable insights for major market players, providers, distributors, and other stakeholders in Nanomedicine Market.

In-depth global Nanomedicine Market taxonomy presented in this Report offers detailed insights about each of the market segments and their sub-segments, which are categorized based on t par various parameters. An exhaustive regional evaluation of global Nanomedicine Market divides global market landscape into essential geographies.

Regional prognosis and country-wise analysis of Nanomedicine Market Allows for the analysis of multi-faceted operation of marketplace in all of the crucial markets. This information intends to provide a broader scope of report to readers and identify the most relevant profitable areas in global market place.

Taxonomy and geographic analysis of the international Nanomedicine Market enables readers to see profits in present chances and catch upcoming growth chances even until they approach the market location. The analysis given in report is only meant to unroll the economic, societal, regulatory and political situations of this market specific to each area and country, which could help potential market entrants in Nanomedicine Market landscape to comprehend the nitty-gritty of target market areas and invent their plans accordingly.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2734725&licType=S&source=atm

Nanomedicine Market Table of Contents

View original post here:
Nanomedicine Market 2019 by Rising-Trends, Growth Analysis, Industry Share, Product Types, User-Demand, Business Strategy and Comprehensive Valuation...

Increase in the Adoption of Healthcare Nanotechnology (Nanomedicine) to Propel the Growth of the Healthcare Nanotechnology (Nanomedicine) Market…

Posted on October 29, 2020 by Prof Baldwin

This report presents the worldwide Healthcare Nanotechnology (Nanomedicine) market size (value, production and consumption), splits the breakdown (data status 2018 and forecast to 2025), by manufacturers, region, type and application.

This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

Top Companies in the Global Healthcare Nanotechnology (Nanomedicine) Market:

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

The report provides a valuable source of insightful data for business strategists and competitive analysis of Healthcare Nanotechnology (Nanomedicine) Market. It provides the Healthcare Nanotechnology (Nanomedicine) industry overview with growth analysis and futuristic cost, revenue and many other aspects. The research analysts provide an elaborate description of the value chain and its distributor analysis. This Tire Healthcare Nanotechnology (Nanomedicine) study provides comprehensive data which enhances the understanding, scope and application of this report.

Influence of the Healthcare Nanotechnology (Nanomedicine) market report:

-Comprehensive assessment of all opportunities and risk in the Healthcare Nanotechnology (Nanomedicine) market.

Healthcare Nanotechnology (Nanomedicine) market recent innovations and major events.

-Detailed study of business strategies for growth of the Healthcare Nanotechnology (Nanomedicine) market-leading players.

-Conclusive study about the growth plot of Healthcare Nanotechnology (Nanomedicine) market for forthcoming years.

-In-depth understanding of Healthcare Nanotechnology (Nanomedicine) market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Healthcare Nanotechnology (Nanomedicine) market.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

The report has 150 tables and figures browse the report description and TOC:

Table of Contents

1 Study Coverage

1.1 Healthcare Nanotechnology (Nanomedicine) Product

1.2 Key Market Segments in This Study

1.3 Key Manufacturers Covered

1.4 Market by Type

1.4.1 Global Healthcare Nanotechnology (Nanomedicine) Market Size Growth Rate by Type

1.4.2 Hydraulic Dredges

1.4.3 Hopper Dredges

1.4.4 Mechanical Dredges

1.5 Market by Application

1.5.1 Global Healthcare Nanotechnology (Nanomedicine) Market Size Growth Rate by Application

2 Executive Summary

2.1 Global Healthcare Nanotechnology (Nanomedicine) Market Size

2.1.1 Global Healthcare Nanotechnology (Nanomedicine) Revenue 2014-2025

2.1.2 Global Healthcare Nanotechnology (Nanomedicine) Production 2014-2025

2.2 Healthcare Nanotechnology (Nanomedicine) Growth Rate (CAGR) 2019-2025

2.3 Analysis of Competitive Landscape

2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

2.3.2 Key Healthcare Nanotechnology (Nanomedicine) Manufacturers

2.3.2.1 Healthcare Nanotechnology (Nanomedicine) Manufacturing Base Distribution, Headquarters

2.3.2.2 Manufacturers Healthcare Nanotechnology (Nanomedicine) Product Offered

2.3.2.3 Date of Manufacturers Enter into Healthcare Nanotechnology (Nanomedicine) Market

2.4 Key Trends for Healthcare Nanotechnology (Nanomedicine) Markets & Products

3 Market Size by Manufacturers

3.1 Healthcare Nanotechnology (Nanomedicine) Production by Manufacturers

3.1.1 Healthcare Nanotechnology (Nanomedicine) Production by Manufacturers

3.1.2 Healthcare Nanotechnology (Nanomedicine) Production Market Share by Manufacturers

3.2 Healthcare Nanotechnology (Nanomedicine) Revenue by Manufacturers

3.2.1 Healthcare Nanotechnology (Nanomedicine) Revenue by Manufacturers (2019-2025)

3.2.2 Healthcare Nanotechnology (Nanomedicine) Revenue Share by Manufacturers (2019-2025)

3.3 Healthcare Nanotechnology (Nanomedicine) Price by Manufacturers

3.4 Mergers & Acquisitions, Expansion Plans

More Information.

See the rest here:
Increase in the Adoption of Healthcare Nanotechnology (Nanomedicine) to Propel the Growth of the Healthcare Nanotechnology (Nanomedicine) Market...

Healthcare Nanotechnology (Nanomedicine) Market Share, Revenue, And Average Worth By Makers Shared In An Exceedingly Latest Analysis Report – Cole of…

Posted on May 14, 2020 by Prof Baldwin

The Healthcare Nanotechnology (Nanomedicine) market report [6 Years Forecast 2020-2026] focuses on the COVID19 Outbreak Impact analysis of key points influencing the growth of the market. Providing info like market competitive situation, product scope, market overview, opportunities, driving force and market risks. Profile the Top Key Players of Healthcare Nanotechnology (Nanomedicine), with sales, revenue and global market share of Healthcare Nanotechnology (Nanomedicine) are analyzed emphatically by landscape contrast and speak to info. Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The Healthcare Nanotechnology (Nanomedicine) market business development trends and selling channels square measure analyzed. From a global perspective, It also represents overall industry size by analyzing qualitative insights and historical data.

The study encompasses profiles of major companies operating in the global Healthcare Nanotechnology (Nanomedicine) market. Key players profiled in the report includes : Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith&Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International, and among others.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Healthcare Nanotechnology (Nanomedicine) Market @https://www.researchmoz.us/enquiry.php?type=S&repid2041239

The Healthcare Nanotechnology (Nanomedicine) market report provides a comprehensive analysis of:Industry overview, cost structure analysis, technical data and competitive analysis, topmost players analysis, development trend analysis, overall market overview, regional market analysis, consumers analysis and marketing type analysis.

Scope of Healthcare Nanotechnology (Nanomedicine) Market:

The global Healthcare Nanotechnology (Nanomedicine) market is valued at million US$ in 2019 and will reach million US$ by the end of 2026, growing at a CAGR of during 2020-2026. The objectives of this study are to define, segment, and project the size of the Healthcare Nanotechnology (Nanomedicine) market based on company, product type, application and key regions.

This report studies the global market size of Healthcare Nanotechnology (Nanomedicine) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Healthcare Nanotechnology (Nanomedicine) in these regions.

This research report categorizes the global Healthcare Nanotechnology (Nanomedicine) market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, customers, research findings & conclusion, appendix & data source and Porters Five Forces Analysis.

The end users/applications and product categories analysis:

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate foreach application.

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid2041239

(*Fill the form and our sales representative will get back to you for assistance)

Healthcare Nanotechnology (Nanomedicine) Market The Regional analysis covers:

Key Takeaways and Reasons To Buy Healthcare Nanotechnology (Nanomedicine) Market Report:

And Many More.Contact Us:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Follow us on LinkedIn @ http://bit.ly/2RtaFUo

Follow me on : https://marketnews-24.blogspot.com/

See the rest here:
Healthcare Nanotechnology (Nanomedicine) Market Share, Revenue, And Average Worth By Makers Shared In An Exceedingly Latest Analysis Report - Cole of...

Global Radiocontrast Agent Market 2020 with Coronavirus (COVID-19) Impact Analysis | likewise Industry is Booming Globaly with Top Players GE…

Posted on July 10, 2020 by Prof Baldwin

Global Radiocontrast Agent Market: Competitive Analysis

The latest report on the globalRadiocontrast Agent marketpublished by theMarket Data Analyticsprovides a comprehensive study of the Radiocontrast Agent market. This research study includes historical data from 2015-2018 and the forecast from 2019 to 2026. The Radiocontrast Agent report covers the latest impact ofCOVID-19on the Radiocontrast Agent market. The pandemic has affected every market around the globe in a negative way. As the world still struggles to recover from the COVID-19 situation it will take a long time for every market to recover its losses. The latest report on the global Radiocontrast Agent market provides you with each and every details about the Radiocontrast Agent market, that is, the current and the future market scenario along with how it was in the past few years.

Request a sample copy of this report::https://www.marketdataanalytics.biz/worldwide-radiocontrast-agent-market-report-2020-industry-analysis-size-40083.html#request-sample

As per our research analysts the impact of COVID-19 has strongly affected the future market opportunities, revenue growth graph, and the profit gains of the business. The report on the global Radiocontrast Agent market consists of more than 25 tables and above 30 figures. The complete report includes more than 150 pages and is available in PDF format.

The research on the Radiocontrast Agent market includes the latest opinions of the market experts as to how the market has been affected by COVID-19 and how the market scenario has changed in the past four months. The research analysts have done a thorough research and have achieved the latest market numbers and the compound annual growth rate.

Read Full Research Report@https://www.marketdataanalytics.biz/worldwide-radiocontrast-agent-market-report-2020-industry-analysis-size-40083.html

The report details are segregated into the market overview, scope of the market, research methodologies used, market drivers, restraints, opportunities, and challenges. The other quantitative and qualitative data includes the market segmentation, regional bifurcation, and the profiling of the industry players.

The market is segmented into{Barium-based Radiocontrast Agent, Iodinated Radiocontrast Agent, Gadolinium-based Radiocontrast Agent, Microbubble Radiocontrast Agent};{Radiology, Interventional Radiology, Interventional Cardiology}. The geographical presence of the Radiocontrast Agent market is categorized mainly into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Some of the major industry players included within the Radiocontrast Agent market study includesGE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany), Guerbet (France), Lantheus (US), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India), Spago Nanomedicine (Sweden), Taejoon Pharm (South.

The data provided in the global Radiocontrast Agent market is highly accurate and reliable thus enabling the client to better understand the current market size and position.

If Any Inquiry of Radiocontrast Agent Report:https://www.marketdataanalytics.biz/worldwide-radiocontrast-agent-market-report-2020-industry-analysis-size-40083.html#inquiry-for-buying

Benefits of Buying this Market Research Report:

1.Analyst advocacy:Get correct answers of your queries from our analysts team of experts before and after purchasing the report.2.Meet Customers Requirements:Our expert team will assist with all your research requirements and customize the report.3.Unique Expertise:We centre around the quality standards and reliability of the report.4.One of a kind Expertise:Experts will give splendid bits of knowledge about the report.

Read the original here:
Global Radiocontrast Agent Market 2020 with Coronavirus (COVID-19) Impact Analysis | likewise Industry is Booming Globaly with Top Players GE...

New Comprehensive Report on Nanomedicine Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like – Jewish Life News

Posted on July 10, 2020 by Prof Baldwin

Nanomedicine Market Overview 2020 2025

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The risingtechnology in Nanomedicine Marketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/91246

Key Competitors of the Global Nanomedicine Market are: , GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A,

Historical data available in the report elaborates on the development of the Nanomedicine on national, regional and international levels. Nanomedicine Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis.

Major Product Types covered are:Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery

Major Applications of Nanomedicine covered are:Clinical CardiologyUrologyGeneticsOrthopedicsOphthalmology

This study report on global Nanomedicine market throws light on the crucial trends and dynamics impacting the development of the market, including the restraints, drivers, and opportunities.

To get this report at a profitable rate.: https://reportsinsights.com/discount/91246

The fundamental purpose of Nanomedicine Market report is to provide a correct and strategic analysis of the Nanomedicine industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

Market Scenario:

The report further highlights the development trends in the global Nanomedicine market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Highlights following key factors:

:-Business descriptionA detailed description of the companys operations and business divisions.:-Corporate strategyAnalysts summarization of the companys business strategy.:-SWOT AnalysisA detailed analysis of the companys strengths, weakness, opportunities and threats.:-Company historyProgression of key events associated with the company.:-Major products and servicesA list of major products, services and brands of the company.:-Key competitorsA list of key competitors to the company.:-Important locations and subsidiariesA list and contact details of key locations and subsidiaries of the company.:-Detailed financial ratios for the past five yearsThe latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Our report offers:

Market share assessments for the regional and country level segments. Market share analysis of the top industry players. Strategic recommendations for the new entrants. Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets. Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). Strategic recommendations in key business segments based on the market estimations. Competitive landscaping mapping the key common trends. Company profiling with detailed strategies, financials, and recent developments. Supply chain trends mapping the latest technological advancements.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://reportsinsights.com/industry-forecast/Nanomedicine-Market-91246

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

See the original post here:
New Comprehensive Report on Nanomedicine Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like - Jewish Life News

Polymeric Nanoparticles and the Future of Gene Delivery Methods – AZoNano

Posted on January 21, 2022 by Prof Baldwin

Accidental discoveries have always led to intriguing research in science, and one such incident by a group of researchers has been published in the journal American Chemical Society.

Image Credit:Billion Photos/Shutterstock.com

Polymeric nanoparticles have so far been proven to be useful for biomedical applications such as for the fabrication of nanostructures; however, their natural function for biological activities has not received much attention. This article will uncover the natural disposition of polymeric nanoparticles for function in biological activities such as targeting submandibular salivary glands.

A major challenge within drug delivery and nanomedicine consist of the ability to target specific tissues.

While there have been increased efforts in this area by innovative researchers through enhancing the selectivity of current nanomedicine drug delivery systems as well as novel strategies to increase targeting, this challenge has not yet been overcome.

The field of nanomedicine thus far has attempted to target specific tissues by utilizing ligands to identify and recognize receptors located on tissue-specific cells. This has resulted in ligands such as antibodies, peptides, aptamers, and others being conjugated onto nanoparticle surfaces, allowing functionalization and increasing the specificity of drug delivery systems. Still, with complex designs, there is difficulty translating a ready-made product for clinical use.

The use of unmodified nanoparticles with intrinsic biological activities could be potentially used to decrease the level of processing required for a fully functional and functionalized drug delivery system. This has made biological macromolecules such as peptides, nucleic acids, and proteins desirable due to their natural ability to have specific molecular interactions with tissues.

Additionally, synthetic polymers can also be exploited for this purpose. They also possess the ability to have interactions for targeting biological functions due to moieties that selectively interact with targets to interfere with their operations.

However, with polymeric nanoparticles being widely used as a drug carrier in nanomedical research, the use of these specialized particles would be useful for the purpose of tissue targeting.

Researchers within this particular study found that polyethyleniminepoly(lactic-co-glycolic acid)2(PEIPLGA), usually used in gene and protein delivery, can mediate the targeting of submandibular salivary glands of mice after being intravenously injected for in vivo experimentation.

The research team found that unmodified polyethyleniminepoly(lactic-co-glycolic acid)2(PEIPLGA) nanoparticles with the hydrophilic PEI fully exposed on the surface around the aqueous phase could selectively accumulate in these mice submandibular salivary glands due to a high affinity with acetylcholine receptors in the specific tissue.

This is comparable to FDA-approved drugs such as muscarinic acetylcholine receptor subtype 3 (M3 receptor)-binding drugs. This illustrates the potential similarity in efficacy, a promising step for a novel drug system utilizing nanomedicine in the form of polymeric nanoparticles for gene targeting.

PEIPLGA nanoparticles can adsorb many negatively charged biological molecules such as RNA, protein, and DNA and have already been commonly utilized for the delivery of nucleic acid or protein drugs through nonselective static electric attraction.

However, the novel aspect of this particular research focused on PEI-PLGA nanoparticles being able to interact with the M3 acetylcholine receptor, which is expressed in a large volume in the submandibular salivary glands.

The development of synthetic polymers such as PEI-PLGA nanoparticles for biological applications can illustrate the interaction of polymers and proteins and can aid in the development of design strategies for nanomedical drug systems.

Additionally, this research would be useful for the development of M3 receptor-targeted therapies to enhance the treatment of diseases relating to the expression of the M3 receptor. An example of such a disorder includes Sjgren syndrome (SS), an autoimmune disease that affects exocrine glands, including salivary and lacrimal glands.

This receptor is also overexpressed in other organs such as the brain, with cholinergic transmission at muscarinic acetylcholine receptors being critical for higher brain function, including learning and memory and a loss of synapses resulting in symptoms relating to Alzheimers disease.

However, while this potential for brain treatment for motor neuron diseases can be technically possible, further research is required as few PEI-PLGA nanoparticles have been observed in the brain, which may be due to the blood-brain barrier.

The researchers have theorized that other muscarinic receptor subtypes such as M1 receptors are also overexpressed in the submandibular gland, so improving the selectivity of PEI-PLGA to target these subtypes can also be a research point.

While no obvious change was found in the level of salivary secretion within mice injected with PEI-PLGA nanoparticles within 24 hours, the targeting ability of these novel polymeric nanoparticles for biological activities is a promising start for possible interference in M3 signaling pathways and function.

This research can be exploited for many useful applications as summarized above and further illustrates the significance of nanomedicine in advancing diseases.

Continue reading: Green Synthesis of Ag Nanoparticles for Antibacterial Applications.

Haam, J. and Yakel, J., (2017)Cholinergic modulation of the hippocampal region and memory function.Journal of Neurochemistry, 142, pp.111-121. Available at: https://doi.org/10.1111/jnc.14052

Heller Brown, J. and Laiken, N., (2012)Acetylcholine and Muscarinic Receptors.Primer on the Autonomic Nervous System, pp.75-78. Available at: https://doi.org/10.1016/B978-0-12-386525-0.00015-9

Xu, J., Wan, K., Wang, H., Shi, X., Wang, J., Zhong, Y., Gao, C., Zhang, Y. and Nie, G., (2021)PolyethyleniminePoly(lactic-co-glycolic acid)2 Nanoparticles Show an Innate Targeting Ability to the Submandibular Salivary Gland via the Muscarinic 3 Receptor.ACS Central Science, 7(11), pp.1938-1948. Available at: https://doi.org/10.1021/acscentsci.1c01083

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Select Page ::